Magnetic resonance imaging

The world’s oldest conjoined twins have died – what we know about this rare condition

Retrieved on: 
Friday, April 19, 2024

The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.

Key Points: 
  • The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.
  • Conjoined twins are incredibly rare, accounting for about one or two in every 100,000 births.
  • Because conjoined twins are so rare, it is difficult to know exactly how they come about.

Types of conjoined twins

  • There are 15 recognised types of conjoined twins, based on the various places their bodies fuse.
  • Conjoined twins are usually picked up on routine ultrasound scans performed during pregnancy.
  • Conjoined twins who are diagnosed by imaging are typically delivered by caesarean section.

Separating twins

  • One of the longest operations to separate conjoined twins, who were fused at the cranium, took more than 100 hours.
  • The earliest recorded attempt at surgical separation of conjoined twins dates back to AD945 in Armenia where conjoined brothers lived until middle age before one of them died.
  • Separating conjoined twins requires a significant amount of planning before surgery can begin, including, of course, lots of imaging such as ultrasound, CT and MRI.
  • Twins who share vital organs – or whose organs are fused – have a lower chance of a successful separation.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on: 
Tuesday, April 9, 2024

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points: 
  • SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
  • At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Wednesday, April 3, 2024

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • “Dosing the first subjects in our Phase 2a HERALD study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “We are pleased by the engagement of the clinicians and subjects, demonstrating the need for additional oral MASH therapies.
  • Topline safety and efficacy data from this study are expected in Q4 2024.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points: 
  • “Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
  • We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
  • Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
  • The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

Q Bio Unveils New MRI Technology - Tensor Field Mapping - Advancing Measurement in Medical Imaging

Retrieved on: 
Tuesday, April 9, 2024

Q Bio Inc. , an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM) , a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable.

Key Points: 
  • Q Bio Inc. , an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM) , a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable.
  • "Tensor Field Mapping is more than an innovative technology; it's a vision for the future of medical imaging where frequency, accuracy, and benchmarking with commodity radiomic data is possible," added Clarissa Shen, COO, Q Bio.
  • Q Bio Inc. is committed to advancing medical imaging technology and improving patient outcomes.
  • With the launch of Tensor Field Mapping, the company is at the forefront of a new era in diagnostics and personalized medicine.

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Monday, March 18, 2024

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.

Key Points: 
  • The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison
    SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • Screening of subjects has begun at clinical study sites across the U.S.
    “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile.
  • We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH.
  • The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos Therapeutics.

Kazakhstan Startup CerebraAI Relocates Headquarters to Silicon Valley to Address Severe Emergency Care Diagnostics Gap through Novel Generative AI Medical Imaging Approach

Retrieved on: 
Tuesday, April 2, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240402257293/en/
    Stroke is a leading cause of death and long-term disability in the U.S. and globally.
  • Following algorithm training and extensive studies in Kazakhstan, with over 130,000 patients analyzed, development is currently underway to introduce CerebraAI’s medical imaging software to the U.S. market.
  • “CerebraAI is one of the first deep tech AI startups in Kazakhstan and they are making a meaningful difference in serving humanity with their novel approach to acute ischemic stroke detection.
  • They are pioneering a new future in emergency care medical imaging diagnostics.”

Crown Bioscience Announces New Preclinical and Translational Oncology Data Across Ten Poster Presentations at AACR 2024

Retrieved on: 
Thursday, March 28, 2024

Crown Bioscience , a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting.

Key Points: 
  • Crown Bioscience , a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting.
  • Highlighting its latest research, the company will present ten posters covering a broad spectrum of data from the company's R&D program.
  • The data presented will cover a range of innovative techniques in oncology and immuno-oncology drug discovery and development.
  • Abstracts for all ten poster presentations can be found on a dedicated page, Crown Bioscience AACR posters 2024.